A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
Elizabeth M. Adams(National Institutes of Health), Paul H. Plötz(National Institutes of Health), M. Bartlett(National Institutes of Health), Cheryl Yarboro(National Institutes of Health), Bryce Thornton(National Institutes of Health Clinical Center), Frank Pucino(National Institutes of Health Clinical Center), Thomas A. Fleisher(National Institutes of Health Clinical Center), María L. Villalba(National Institutes of Health), Jeanne E. Hicks(Pain and Rehabilitation Medicine), Charles L. McGarvey(National Institutes of Health)
PubMed
February 1, 1999
Cited by 58
Related Papers
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
|Science|2014|844
Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus Erythematosus
|New England Journal of Medicine|1979|531